Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance

@article{Kamenov2015OvulationIW,
  title={Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance},
  author={Zdravko Kamenov and Georgi Kolarov and Antoaneta Gateva and Gianfranco Carlomagno and Alessandro D. Genazzani},
  journal={Gynecological Endocrinology},
  year={2015},
  volume={31},
  pages={131 - 135}
}
Abstract Background: Insulin resistance plays a key role in the pathogenesis of polycystic ovarian syndrome (PCOS). One of the methods for correcting insulin resistance is using myo-inositol. Aim: The aim of the present study is to evaluate the effectiveness of myo-inositol alone or in combination with clomiphene citrate for (1) induction of ovulation and (2) pregnancy rate in anovulatory women with PCOS and proven insulin resistance. Patients and methods: This study included 50 anovulatory… 

Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial

This study shows that MYO should be considered in the treatment of infertile PCOS patients, as MYO administration increases clinical pregnancy rates, lowers total rFSH dose and the duration of the ovulation induction.

Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women

The combination of MI with α-LA was able to re-establish ovulation, greatly increasing the chances of desired pregnancy and achieving significant progress in the treatment of PCOS MI-resistant patients.

Inositol Treatment and ART Outcomes in Women with PCOS

Current knowledge on ovarian stimulation and ART outcomes following inositol treatment in women with PCOS undergoing in vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI) is summarized.

Inositols in PCOS

The available clinical data suggest that MI, DCI, and their combination in physiological ratio 40:1 with or without other compound could be beneficial for improving metabolic, hormonal, and reproductive aspects of PCOS.

Use of alpha-lactalbumin for the management of PCOS in inositols resistant women.

  • V. Unfer
  • Biology
    European review for medical and pharmacological sciences
  • 2018
Inositols supplementation has proven to be a safe and effective treatment for PCOS women and based on these observations, it is possible to speculate that the co-administration of inositols plus alpha-lactalbumin may be more effective than inositolics alone, providing a clinical efficacy even in the so-called inositol resistant patients.

An innovative approach to polycystic ovary syndrome

The main stages of Vittorio Unfer’s scientific career have been closely intertwined with important phases of the recent pharmacological research about the topic and his researches allowed to identify “the D-Chiro-Inositol Paradox in the Ovary” and the best myo- inositol/D-chiro-inositol ratio (40:1) for the treatment of PCOS.

Myo-Inositol in the Treatment of Teenagers Affected by PCOS

Administration of MI is a safe and effective method to prevent and correct metabolic disorders in teenagers affected by PCOS and with combination of MI and OCPs antiandrogenic effects are enhanced, negative impact of O CPs on weight gain is balanced, and metabolic profile is improved.

Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients

New experimental and clinical evidence with MI plus DCI evidenced the suitability of such integrated approach, and provided promising results, further studies need to investigate thoroughly the molecular mechanism and confirm such preliminary data.

Inositols in Polycystic Ovary Syndrome: An Overview on the Advances

The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review

  • A. GatevaV. UnferZ. Kamenov
  • Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2018
Myo-inositol monotherapy results more effective in preventing and treating GDM even if a larger cohort of studies is needed to better clarify these results.

References

SHOWING 1-10 OF 42 REFERENCES

Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction

  • E. PapaleoV. Unfer A. Ferrari
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2007
Myo-inositol is a simple and safe treatment that is capable of restoring spontaneous ovarian activity and consequently fertility in most patients with PCOS, and did not cause multiple pregnancy.

Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women

  • E. RaffoneP. RizzoV. Benedetto
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2010
Both metformin and MYO, can be considered as first line treatment for restoring normal menstrual cycles in most patients with PCOS, even if MYO treatment seems to be more effective than meetformin.

Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study

  • P. ArtiniO. M. Di Berardino V. Cela
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2013
Myo-inositol administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion, and insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment.

Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients

  • A. GenazzaniA. Prati P. Artini
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2012
The hypothesis that MYO administration is more effective in obese patients with high fasting insulin plasma levels is supported, as well as the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol.

Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome

Evaluating the effects of myo-inositol (MYO), an isoform of inositol, belonging to the vitamin B complex, in the treatment of cutaneous disorders like hirsutism and acne found it to be a simple and safe treatment that ameliorates the metabolic profile of patients with PCOS.

Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.

Treatment of PCOS patients with Myo-inositol provided a decreasing of circulating insulin and serum total testosterone as well as an improvement in metabolic factors.

The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.

The combined therapy myo- inositol plus D-chiro-inositol is able to improve the metabolic profile of PCOS women, therefore, reducing the cardiovascular risk in PCOS patients.

Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome

Myo-inositol administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion and insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index.

Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS.

Data support a beneficial effect of myo-inositol in women with oligomenorrhea and polycystic ovaries in improving ovarian function and there was an inverse relationship between body mass and treatment efficacy.

The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome

The data show that a combination of combined contraceptive pill and MI may be more effective in controlling endocrine, metabolic, and clinical profile in patients with PCOS than OCP alone, and may reduce insulin levels and insulin resistance.